Document B5xLK3R7QY159V8GZ0oJx5dk8
Clegg. Patsy PM SCC
From:
Mallett, Anthony AK SC-CHSE-TM
Sent:
Wednesday, July 12, 2000 3:06 AM
To: Hill, Patsy PM SCC; Cagen, Stuart SZ SCC; Priston, Robert RA SC-CHSE-BP;
Clarke-Sturman, Tony A SIPC-OMF/4
Cc: Young, David K SC-CBAR
Subject:
FW: BZ/SHANGHAI
Importance:
High
FYI, feedback via Exxon on emerging benzene epi study. Regards
Tony Mallett, HSE Toxicology Adviser and Product Steward - Aromatics, London
Shell Chemicals Limited CHSE-TM Shell Centre York Road London, SE1 7NA
Tel: +44 (0)207 934 2392 Fax: +44 (0)207 934 7627 E-mail: anthony.k.mallett@opc.shell.com
From: Sent: To: Cc:
Subject: Importance:
Jacques
christopher.d.money@esso.com[SMTP:christopher.d.money@esso.com] 12 July 2000 07:41 jau@cefic.be Bo.Dmytrasz@concawe.be; cgi@cefic.be; Mallett, Anthony AK SC-CHSE-TM; Ipottenger@dow.com; paul. thomas@mich.elf-atochem.fr FW: BZ/SHANGHAI High
I will ring to discuss this .. I understand that CONCAWE are likely to discuss this on 27th September. One possibility may be to try to have a joint mtg between CONCAWE and APA for the duration of any presentation/discussion etc and then to decide separately how to deal with this.
Chris
> -----Original Message-----
> From:Schnatter, A. R.
> Sent: Friday, July 07,20002:31 PM
> To: 'Roythorne, Christopher'; Money, Chris
> Cc: 'Beatty, Patrick (Chevron)'; Bird, Michael G.
> Subject:
BZ/SHANGHAI
>
> Dear Chrisx2:
>
> It looks as though the expressions of support for the subject project are trickling in from different
companies as we speak. Pat and I are prepared to take the next step of hopefully garnering some
interest and possible support from our European-based colleagues. We were hoping that we could rely
on you as a coordinator/colleague in these discussions, or at least get your thoughts on other kep
players.
>
> We would like to discuss the project among relevant industry groups and other key organizations:
>
SH ELL-MCCLU RG-06S274
> > We would like to make this an agenda item at a future CONCAWE meeting - hopefully in the September time frame. > > > We would also like to discuss this amongst Bz producers. Would the APA be the relevant group? Would it be beneficial to discuss it with any other groups at ECETOC or CEFIC? Would either of you be willing to coordinate? > > > We'd also like to discuss possible roles for WHO/IPCS, IARC and ILO. We have an ILO contact, and Michale Bird will likely be able to help us with IARC, but do either of you have any recommendations for entry into WHO/IPCS? > > If either of you have any other suggestions on possible stakeholders, we'd value this input very much. > > We'd also value your opinion on whether the PI's (Irons and Wong) ought to be part of the discussions. Our preliminary thought was that they weren't essential at the industry meetings, but they might be more critical for the IARC and IPCS interfaces. Any thoughts on this? > > Thanks for whatever assistance you can provide on this. It promises to be an exciting challenge. > > Sincerely, > > Rob Schnatter >
> --------------------------------------------------------------------------
> > A. Robert Schnatter > ExxonMobil Biomedical Sciences, Inc. > Epidemiology and Health Surveillance Section > PO Box 971, Rte 22 East, Annandale, NJ 08801-0971 > Room LF-252, 908-730-1101, fax: 1192, pager:732-437-4702 > arschna@erenj.com > >
SH ELL-MCCLU RG-06S27S